Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 35 Records) |
| Query Trace: Lung Neoplasms and CYP3A4[original query] |
|---|
| Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Mar 26 (7): 1119-27. Rudin Charles M, Liu Wanqing, Desai Apurva, Karrison Theodore, Jiang Xuemin, Janisch Linda, Das Soma, Ramirez Jacqueline, Poonkuzhali Balasubramanian, Schuetz Erin, Fackenthal Donna Lee, Chen Peixian, Armstrong Deborah K, Brahmer Julie R, Fleming Gini F, Vokes Everett E, Carducci Michael A, Ratain Mark |
| A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 2008 Jun 29 (6): 1164-9. Zienolddiny Shanbeh, Campa Daniele, Lind Helge, Ryberg David, Skaug Vidar, Stangeland Lodve B, Canzian Federico, Haugen Aa |
| CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. Carcinogenesis 2009 Jul 30 (7): 1161-9. Timofeeva Maria N, Kropp Silke, Sauter Wiebke, Beckmann Lars, Rosenberger Albert, Illig Thomas, Jäger Birgit, Mittelstrass Kirstin, Dienemann Hendrik, , Bartsch Helmut, Bickeböller Heike, Chang-Claude Jenny C, Risch Angela, Wichmann Heinz-Eri |
| Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jul 27 (21): 3540-6. Gandara David R, Kawaguchi Tomoya, Crowley John, Moon James, Furuse Kiyoyuki, Kawahara Masaaki, Teramukai Satoshi, Ohe Yuichiro, Kubota Kaoru, Williamson Stephen K, Gautschi Oliver, Lenz Heinz Josef, McLeod Howard L, Lara Primo N, Coltman Charles Arthur, Fukuoka Masahiro, Saijo Nagahiro, Fukushima Masanori, Mack Philip |
| A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jun 16 (11): 3078-87. Lind Joline S W, Dingemans Anne-Marie C, Groen Harry J M, Thunnissen Frederik B, Bekers Otto, Heideman Daniëlle A M, Honeywell Richard J, Giovannetti Elisa, Peters Godefridus J, Postmus Pieter E, van Suylen Robert Jan, Smit Egbert |
| Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. European journal of clinical pharmacology 2011 Jul 67 (7): 693-700. Bergmann Troels K, Gréen Henrik, Brasch-Andersen Charlotte, Mirza Mansoor R, Herrstedt Jørn, Hølund Berit, du Bois Andreas, Damkier Per, Vach Werner, Brosen Kim, Peterson Cu |
| Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. Clinical lung cancer 2013 Sep 14 (5): 502-7. Takimoto Takayuki, Kijima Takashi, Otani Yasushi, Nonen Shinpei, Namba Yoshinobu, Mori Masahide, Yokota Soichiro, Minami Seigo, Komuta Kiyoshi, Uchida Junji, Imamura Fumio, Furukawa Mitsugi, Tsuruta Naotoshi, Fujio Yasushi, Azuma Junichi, Tachibana Isao, Kumanogoh Atsus |
| Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014 Feb 35 (2): 1671-8. Islam Mohammad Safiqul, Mostofa A G M, Ahmed Maizbha Uddin, Bin Sayeed Muhammad Shahdaat, Hassan Md Rajib, Hasnat Ab |
| Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects. Clinical drug investigation 2015 Jan 35 (1): 31-43. Choi Hyun-Gyu, Jeon Ji-Young, Im Yong-Jin, Kim Yunjeong, Song Eun-Kee, Seo Young-Hwan, Cho Seok-Je, Kim Min-G |
| Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clinical lung cancer 2015 Jul 16 (4): 274-81. Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masato |
| Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2016 Mar 93 69-76. Hirose Takashi, Fujita Ken-Ichi, Kusumoto Sojiro, Oki Yasunari, Murata Yasunori, Sugiyama Tomohide, Ishida Hiroo, Shirai Takao, Nakashima Masanao, Yamaoka Toshimitsu, Okuda Kentaro, Ohmori Tohru, Sasaki Yasutsu |
| Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. Journal of clinical pharmacology 2018 04 58 (4): 485-493. Chen Yingxue, Zhou Diansong, Tang Weifeng, Zhou Wangda, Al-Huniti Nidal, Masson Er |
| Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity. Anti-cancer drugs 2018 3 29 (5): 471-476. Park Yoon Hee, Cho Soyeon, Yee Jeong, Kim Jae Youn, Rhie Sandy Jeong, Gwak Hye S |
| Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study. BMC cancer 2018 10 18 (1): 988. Kim Min Kyoung, Yee Jeong, Cho Yoon Sook, Jang Hong Won, Han Ji Min, Gwak Hye S |
| Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters. Biological & pharmaceutical bulletin 2018 41 (1): 47-56. Endo-Tsukude Chihiro, Sasaki Ji-Ichiro, Saeki Sho, Iwamoto Norihiro, Inaba Megumi, Ushijima Sunao, Kishi Hiroto, Fujii Shinji, Semba Hiroshi, Kashiwabara Kosuke, Tsubata Yukari, Hayashi Mitsuhiro, Kai Yuki, Saito Hideyuki, Isobe Takeshi, Kohrogi Hirotsugu, Hamada Akino |
| CYP3A4 genetic variants are associated with susceptibility of non-small cell lung cancer in a Shaanxi Han population. Genomics 2020 May . Jia Zhuoqi, Zhou Weiru, Zhang Guangjian, Fu Junke, Li Daxu, Ren |
| Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients with Non-Small Cell Lung Cancer. Turkish journal of pharmaceutical sciences 2020 5 14 (3): 319-323. I?can Mümtaz, Ada Ahmet O? |
| Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study. European journal of clinical pharmacology 2020 May . Han Ji Min, Han Hye Won, Yee Jeong, Kim Min Kyoung, Moon Jin Young, Cho Soyeon, Jung Dasom, Cho Yoon Sook, Seo Inyoung, Kim Jae Youn, Gwak Hye S |
| The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. Annals of translational medicine 2019 Dec 7 (24): 806. Ma Yuxiang, Xin Shuang, Lin Qingguang, Zhuang Wei, Zhao Yuanyuan, Zhu Xia, Zhao Hongyun, Huang Min, Xun Xu, Yang Yunpeng, Fang Wenfeng, Zhang Li, Wang Xuedi |
| Establishment of predicting equation for individual sufentanil dosage postoperatively based on gene polymorphisms. Pain practice : the official journal of World Institute of Pain 2021 5 22 (1): 39-46. Cheng Huawei, Zeng Rong, Kong Lingsuo, Ding Conglan, He Yifu, Zhuang Wei, Sun Yanc |
| Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer. Investigational new drugs 2022 9 40 (6): 1254-1262. Yokota Hayato, Sato Kazuhiro, Sakamoto Sho, Okuda Yuji, Fukuda Natsuki, Asano Mariko, Takeda Masahide, Nakayama Katsutoshi, Miura Masato |
| Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities. Anti-cancer drugs 2022 Aug . Kwok Wang Chun, Lam David Chi Leung, Ip Mary Sau Man, Tam Terence Chi Chun, Ho James Chung M |
| Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer. Frontiers in pharmacology 2022 13 918219. Tan Tingfei, Han Gongwei, Cheng Ziwei, Jiang Jiemei, Zhang Li, Xia Zitong, Wang Xinmeng, Xia Qu |
| Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant. European journal of clinical pharmacology 2022 1 78 (4): 613-621. Hibino Hideyuki, Sakiyama Naomi, Makino Yoshinori, Makihara-Ando Reiko, Horinouchi Hidehito, Fujiwara Yutaka, Kanda Shintaro, Goto Yasushi, Yoshida Tatsuya, Okuma Yusuke, Shinno Yuki, Murakami Shuji, Hashimoto Hironobu, Akiyoshi Takeshi, Imaoka Ayuko, Ohe Yuichiro, Yamaguchi Masakazu, Ohtani Hisaka |
| Study on individualized analgesia guided by CYP3A4/5 polymorphisms in perioperative thoracoscopic surgery. American journal of translational research 2022 1 13 (12): 14211-14219. Wang Shengyan, Yao Yibing, Kong Min, Zhou Xuyan, Shen |
| Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. EClinicalMedicine 2023 5 59 101955. G D Marijn Veerman, Rene J Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J van der Wekken, Idris Bahce, Lizza E L Hendriks, Sander Croes, Christi M J Steendam, Evert de Jonge, Stijn L W Koolen, Neeltje Steeghs, Ron H N van Schaik, Egbert F Smit, Anne-Marie C Dingemans, Alwin D R Huitema, Ron H J Mathijss |
| Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib. Frontiers in pharmacology 2023 12 14 1234262. Bole Li, Shan Liu, Honglei Feng, Chunshuang Du, Liman Wei, Jie Zhang, Guangwei Jia, Chunnuan |
| CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients. Frontiers in pharmacology 2023 11 14 1222435. Teerapat Majam, Chonlaphat Sukasem, Thanyanan Reungwetwattana, Phichai Chansriwong, Chalirmporn Atasilp, Narumol Trachu, Thanaporn Thamrongjirapat, Rattanaporn Sukprasong, Jennis Meanwattha |
| Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024 12 . Niels Heersche, Daan A C Lanser, M Benthe Muntinghe-Wagenaar, Ma Ida Mohmaed Ali, Ezgi B Ulas, Tessa M A Trooster, Evert de Jonge, Esther Oomen-de Hoop, Marthe S Paats, Idris Bahce, Sander Croes, Lizza E L Hendriks, Anthonie J van der Wekken, Anne-Marie C Dingemans, Alwin D R Huitema, Ron H N van Schaik, Ron H J Mathijssen, G D Marijn Veerm |
| CYP3A4 gene expression discloses individual differences in postoperative pain susceptibility and drug treatment response in patients with lung cancer. International journal of clinical and experimental pathology 2024 10 17 (9): 287-297. Xiunan Jia, Xi Nan, Shiqi Diao, Dongxin Wang, Tongrao Wang, Dongmei Fu, Chunyan Ni, Ying Chang, Jixin Liu, Xitong Zhang, Hongling Cao, Xiaoyu Zhang, Dongxue Li, Qing Zu, Gang Liu, Zongming L |
- Page last reviewed:Feb 1, 2024
- Content source: